Thyroid Hormone Autoantibodies: Are They a Better Marker to Detect Early Thyroid Damage in Patients with Hematologic Cancers Receiving Tyrosine Kinase Inhibitor or Immunoregulatory Drug Treatments?

Mondello, Patrizia; Mian, Michael; Pitini, Vincenzo; Cuzzocrea, Salvatore; Sindoni, Alessandro; Galletti, M.; Mandolfino, M.; Santoro, Domenico; Mondello, Stefania; Aloisi, C; Altavilla, Giuseppe; Benvenga, Salvatore

doi:10.3747/co.23.3026

Cited by 8 publications

(10 citation statements)

References 12 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sonographic signs of thyroiditis were detected only in MM (10%) and NHL (13%). In another study on the same patients and controls [5], 13% of patients and 1% of controls (P = 0.0006) were THAb positive. THAbs were observed in four malignancies (MM=3/ 22, NHL=5/36, CLL=1/4, CML=2/8, PV=0/12).…”

mentioning

confidence: 85%

“…THAb are rare in the general population (<1%), but relatively frequent (>20%) in autoimmune thyroid diseases (AITD) and both autoimmune and nonautoimmune nonthyroid diseases (NAINTD) [4,5]. Amongst NAINTD, there are Waldenstrom's macroglobulinemia and other haematologic malignancies including one cause of AL amyloidosis: multiple myeloma (MM) [5].…”

mentioning

confidence: 99%

“…Amongst NAINTD, there are Waldenstrom's macroglobulinemia and other haematologic malignancies including one cause of AL amyloidosis: multiple myeloma (MM) [5].…”

mentioning

confidence: 99%

See 2 more Smart Citations

AL amyloidosis, hypothyroidism and reduced tissue availability of thyroid hormones by thyroid hormone‐binding immunoglobulin: a new possible perspective

Benvenga

Guarneri

2017

J Intern Med

Self Cite

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 85%

mentioning

confidence: 99%

See 1 more Smart Citation

AL amyloidosis, hypothyroidism and reduced tissue availability of thyroid hormones by thyroid hormone‐binding immunoglobulin: a new possible perspective

Benvenga

Guarneri

2017

J Intern Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Indeed, in those patients, the rate of THAb positivity increased by eightfold (from 5 to 40%) over the period 1975–2005 ( 6 , 8 ). THAb are found in patients with Graves’ disease in around one-third of cases ( 8 , 9 ). Also, the real prevalence of THAb may be underestimated because they are not routinely assayed and can appear transiently in serum ( 8 , 10 ).…”

Section: Introductionmentioning

confidence: 99%

Serum Thyroid Hormone Antibodies Are Frequent in Patients with Polyglandular Autoimmune Syndrome Type 3, Particularly in Those Who Require Thyroxine Treatment

et al. 2017

View full text Add to dashboard Cite

Polyglandular autoimmune syndrome (PAS) type 3 consists of autoimmune thyroid disease (AITD) coexisting with ≥1 non-thyroidal autoimmune disease (NTAID) other than Addison’s disease and hypoparathyroidism. We evaluated the prevalence and repertoire of thyroid hormones antibodies (THAb) in PAS-3 patients. Using a radioimmunoprecipation technique, we measured THAb (T3IgM, T3IgG, T4IgM, and T4IgG) in 107 PAS-3 patients and 88 controls (patients with AITD without any NTAID). Based on the selective coexistence of AITD with one NTAID (chronic autoimmune gastritis, non-segmental vitiligo or celiac disease), patients were divided into group 1 (chronic autoimmune gastritis positive, n = 64), group 2 (non-segmental vitiligo positive, n = 24), and group 3 (celiac disease positive, n = 15). At least one of the four THAb was detected in 45 PAS-3 patients (42.1%) and 28 controls (31.8%, P = 0.14), with similar rates in the three PAS-3 groups. The rates of T3Ab, T4Ab, and T3 + T4Ab were similar in groups 1 and 2, while in group 3, T3Ab was undetected (P = 0.02). In PAS-3 patients, the rate of levothyroxine treatment was greater in THAb-positive patients compared to THAb-negative patients (76.7 vs. 56.1%, P = 0.03, RR = 1.4, 95% CI 1.03–1.81). Not unexpectedly, levothyroxine daily dose was significantly higher in group 1 and group 3, namely in patients with gastrointestinal disorders, compared to group 2 (1.9 ± 0.4 and 1.8 ± 0.3 vs. 1.5 ± 0.2 μg/kg body weight, P = 0.0005 and P = 0.004). Almost half of PAS-3 patients have THAb, whose repertoire is similar if chronic autoimmune gastritis or celiac disease is present. A prospective study would confirm whether THAb positivity predicts greater likelihood of requiring levothyroxine treatment.

show abstract

“…Guest Editor Prof. Antonelli whose roots of endocrinology and immunology go back into the 1980's and I myself have met at one of the annual Endocrine Society meetings via introduction by Prof. Salvatore Benvenga who has also worked at the NIH in Bethesda, MD, in the past [55][56][57][58][59][60][61]. This guest issue begins with a review on the immune cell-adipocyte crosstalk as an important regulator not only of adipose tissue function, but also of systemic metabolism and homeostasis [62].…”

mentioning

confidence: 99%

Immunoendocrinology: When (neuro)endocrinology and immunology meet

Koch

Antonelli

2018

Rev Endocr Metab Disord

View full text Add to dashboard Cite

For this guest issue, Prof. Antonelli assembled a panel of international expert contributors to discuss current aspects of immunoendocrinology. There is increasing awareness of the intricate and intertwined relationship between the endocrine and immune system. In part, this is caused by an explosion of various immunotherapies including cellular immunotherapy (for instance, sipuleucel-T (Provenge), tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta)), antibody-based therapy (i.e. rituximab (Rituxan, Mabthera), atezolizumab (Tecentriq), avelumab (Bavencio), ofatumumab (Arzerra), alemtuzumab (Campath-1H), durvalumab (Imfinzi), ipilimumab (Yervoy), tremelimumab, pembrolizumab, nivolumab (Opdivo)), cytokine therapy (i.e. interferon, interleukin-2), combination immunotherapy, and others. Among antibody based immunotherapies are the checkpoint inhibitor antibodies with ipilimumab being the first antibody approved by the Federal Food and Drug Administration (FDA). More and more immune-related adverse events of immune checkpoint inhibitor treatment are being unraveled and algorithms for acute management of endocrine complications have been proposed [1-8]. My first encounter with immunology occurred while studying at the Friedrich-Alexander University of Erlangen-Nuremberg in the 1980s and rotating through the Department of Medicine headed by Professor Joachim R. Kalden, who in 1970 reported on the effect of hypophysectomy on the immune system in male Sprague-Dawley strain rats [9]. Many fellow immunologists and rheumatologists trained under Prof. JR Kalden have risen to the top of the field [10-12]. My next immunological encounters, including the occurrence of bullous pemphigoid after treatment with furosemide, happened during residency training at the Ohio State University Medical Center [13] followed by the National Institutes of Health (NIH) which had the largest impact on my education in immunology and its intersection with endocrinology [14]. At the NIH I met many immunology and other experts, including Profs. George Chrousos, Ronald Wilder, Esther Sternberg, Ilias Elenkov, Philip Gold, Julio Licinio, and Thomas Fleisher [15-17]. After departing the NIH and spending a few years in Germany, I had the pleasure to collaborate with visceral and thoracic surgeon expert Prof. Ott and we published a study showing that converting liver transplant recipients from cyclosporine A therapy to steroid-saving tacrolimus monotherapy caused a decline in mean serum cholesterol and high density cholesterol levels but an increase in low density cholesterol serum concentrations, apparently without beneficial effect on the atherogenic lipid profile [18].

show abstract

Thyroid Hormone Autoantibodies: Are They a Better Marker to Detect Early Thyroid Damage in Patients with Hematologic Cancers Receiving Tyrosine Kinase Inhibitor or Immunoregulatory Drug Treatments?

Abstract: Background Unlike cytotoxic agents, novel antineoplastic drugs can variably affect thyroid function and so

Cited by 8 publications

References 12 publications

AL amyloidosis, hypothyroidism and reduced tissue availability of thyroid hormones by thyroid hormone‐binding immunoglobulin: a new possible perspective

AL amyloidosis, hypothyroidism and reduced tissue availability of thyroid hormones by thyroid hormone‐binding immunoglobulin: a new possible perspective

Serum Thyroid Hormone Antibodies Are Frequent in Patients with Polyglandular Autoimmune Syndrome Type 3, Particularly in Those Who Require Thyroxine Treatment

Immunoendocrinology: When (neuro)endocrinology and immunology meet

Contact Info

Product

Resources

About